Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

Claire N. Harrison, Alessandro Maria Vannucchi, Uwe Platzbecker et al. · The Lancet Haematology · 2017

Cited by 321 works. doi:10.1016/s2352-3026(17)30237-5

Authors

References